Doxycycline postexposure prophylaxis (doxyPEP) has the potential to substantially reduce real-world population-level incidence of sexually transmitted infections (STIs), a study in JAMA Internal Medicine suggested.
This conclusion was reached by Stephanie E. Cohen, MD, medical director of the San Francisco City Clinic, Department of Public Health in San Francisco, and colleagues after examining STI trends in an urban population before (July 2021 to October 2022) and after (November 2022 to November 2023) the release of San Francisco’s citywide doxyPEP guidelines in October 2022.
DoxyPEP has proven effective for at-risk persons in clinical trials in the United States and France.
Study Details
Across the city there were 6694 cases of chlamydia, 9603 cases of gonorrhea, and 2121 cases of early syphilis in men who have sex…